Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Byoung Chul Cho, Iveta Kudaba et al.|Journal of Clinical Oncology|2022Cited by 334
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancerGilberto de Castro, Byoung Chul Cho, Iveta Kudaba et al.|Regular and Young Investigator Award Abstracts|2021Cited by 17
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.Kevin J. Harrington, Christophe Le Tourneau, Ainara Soria et al.|Journal of Clinical Oncology|2019Cited by 4